BioPharmSignal logoBioPharmSignal

Biotech News

Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline

Spero Therapeutics (SPRO)Spero TherapeuticsCompany update

Amy Rock, Ph.D., appointed Chief Regulatory and Quality Officer, bringing extensive experience in global regulatory strategy, clinical development, and with approvals of novel immunotherapies

Dae Gon Ha, Ph.D., appointed Senior Vice President, Corporate Development, bringing expertise...

Related news

SPROSpero Therapeutics2026-10-15 21:05 EST

Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference

SPROSpero Therapeutics2026-10-02 21:05 EST

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ANTXAN2 Therapeutics2026-11-04 12:00 EST

AN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)

ANTXAN2 Therapeutics2026-11-04 21:00 EST

AN2 Therapeutics to Present at Jefferies Global Healthcare Conference in London

ENTAEnanta Pharmaceuticals2026-10-28 11:00 EST

Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership

IMNNImunon2026-09-10 13:30 EST

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

VIRIVirios Therapeutics2026-06-30 12:45 EST

Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board

View all latest news

Spero Therapeutics

Immunology and Inflammation Company Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious immune-mediated diseases. Its internal strategy now centers on CD40 ligand inhibition. SP001 SP001 is a third-generation, Fc-silent monoclonal antibody targeting CD40 ligand. The molecule is designed to...

Recent company news

SPROSpero Therapeutics2026-11-04 22:05 EST

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SPROSpero Therapeutics2026-11-02 22:05 EST

Spero Therapeutics to Present at Investor Conferences in November

SPROSpero Therapeutics2026-10-26 13:00 EST

Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline

SPROSpero Therapeutics2026-10-26 13:00 EST

Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline

SPROSpero Therapeutics2026-10-26 13:00 EST

Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline

Stock data

Close
1.02 USD
Market cap
163.86M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States